Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Marsi bionics

Explore full profile

Developing disruptive innovative therapies to the healthcare sector

Rivas-Vaciamadrid, SpainFounded 2013Biotech & Life Sciences
Valuation $25–50M Last recorded · 2023
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Marsi bionics and the history behind them.

About Marsi bionics

Marsi Bionics, founded in 2013, is a Spanish medical robotics company that develops and commercializes wearable exoskeletons for patients with neurological conditions and mobility issues. The company originated as a spin-off from the Center for Automation and Robotics (CAR), a joint center of the Spanish National Research Council (CSIC) and the Polytechnic University of Madrid (UPM). The CSIC has been a shareholder in the company since 2019.

The company was founded by Dr. Elena García Armada, a renowned roboticist with a PhD in Industrial Engineering. Her career shifted focus after a 2009 meeting with a young girl left quadriplegic by an accident, which inspired her to engineer pediatric robotic exoskeletons. This led to the creation of Marsi Bionics to transfer the research into societal solutions.

Marsi Bionics' core business is designing and building modular gait exoskeletons for medical applications, serving clients in hospitals and rehabilitation centers. Its products are aimed at improving mobility and quality of life for children and adults with conditions like spinal muscular atrophy (SMA), cerebral palsy, and hemiplegia caused by stroke. A key patented technology is ARES, a system that provides variable stiffness to the robotic joints, mimicking natural muscle function to personalize gait therapy. The company's main products include the ATLAS 2030, the world's first pediatric exoskeleton for overground walking, and the MB-Active Knee (MAK), a single-joint orthosis for adults. The ATLAS 2030 is adjustable for a child's growth and features smart joints that interpret the user's intended movements. In May 2021, the device received its CE marking, enabling its distribution in Spain and internationally.

Source: Dealroom company data

At a glance

Founded
2013
Headquarters
Rivas-Vaciamadrid, Spain
Sector
Biotech & Life Sciences

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • European Innovation Council
  • European Commission
  • Fellow Funders

Series A3 investors entered at this stage

  • Verónica Pascual
  • Ion Ion
  • Orilla Asset Management
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇪🇸 Spain96.3%
🇩🇪 Germany1.9%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Marsi bionics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Marsi bionics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.